.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,241,965

« Back to Dashboard

Details for Patent: 6,241,965

Title: Somatostatin derivatives and their radiolabelled products
Abstract:This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labelled radiodiagnostic agents. Specifically, the invention relates to linear peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabelled with a radioisotope, as well as methods and kits for making, radiolabelling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to linear peptide derivatives and analogues of somatostatin radiolabelled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specicically relates to linear peptide derivatives and analogues of somatostatin radiolabelled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabelling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.
Inventor(s): Dean; Richard T. (Bedford, NH), McBride; William (Summit, NJ)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Apr 22, 1996
Application Number:08/586,670
Claims:1. A radiotherapeutic agent comprising:

a) a linear peptide having a formula:

wherein

X.sup.1 and X.sup.2 are each independently hydrophilic moieties;

A.sup.1, A.sup.2 and C.sup.1 are each independently a lipophilic D-amino acid, a lipophilic L-amino acid, S-alkylated cysteine, penicillamine, homocysteine, or homohomocysteine;

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, or Ain;

B.sup.2 is D-Trp or L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Aec, Apc, Aes, or Aps;

B.sup.4 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, or Aib; and

C.sup.2 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, Nal, or Aib; and

b) a cytotoxic radioisotope.

2. The agent of claim 1, wherein X.sup.1 is selected from the group consisting of an amino acid, a peptide containing no more than 10 amino acid residues, a monosaccharide, an oligosaccharide comprising 10 or fewer saccharide units, a poly(N-carboxyalkyl)amine, and a polyoxyanion; and X.sup.2 is selected from the group consisting of a poly(N-carboxyalkyl)arnine, a polyoxyanion, an amino acid, a peptide containing no more than 10 amino acid residues, a peptide containing no more than 10 amino acid residues and having a carboxyl-terminal amino acid which is reduced to an alcohol, a monosaccharide, and an oligosaccharide comprising 10 or fewer saccharide units.

3. The agent of claim 1 wherein B.sup.1 is phenylalanine or tyrosine, B.sup.2 is D-tryptophan, B.sup.3 is lysine and B.sup.4 is threonine or valine.

4. The agent of claim 1, wherein the radioisotope is selected from the group consisting of iodine-125, iodine-131, astatine-211, scandium-47, copper-67, gallium-72, yttrium-90, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium- 177, rhenium-186, rhenium-188, and bismuth-212.

5. The agent of claim 1, further comprising a non-radioactive metal.

6. A radiotherapeutic multimer comprising:

a) at least two copies of a linear peptide having a formula:

wherein

X.sup.1 and X.sup.2 are each independently hydrophilic moieties;

A.sup.1, A.sup.2 and C.sup.1 are each independently a lipophilic D-amnino acid, a lipophilic L-amino acid, S-alkylated cysteine, penicillamine, homocysteine, or homohomocysteine;

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, or Ain;

B.sup.2 is D-Trp or L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Aec, Apc, Aes, or Aps;

B.sup.4 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, or Aib; and

C.sup.2 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, Nal, or Aib; and

b) a polyvalent linker covalently linked to each of said peptides, wherein the molecular weight of said multimer is less than about 20,000 daltons; and

c) a cytotoxic radioisotope.

7. The multimer of claim 6, wherein the linker is selected from the group consisting of bis-succinimidylmethylether, 4-(2,2-dimethylacetyl)benzoic acid, N-(2-(N',N'-bis(2-succinimidoethyl)aminoethyl))-N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, tris(succinimidylethyl)amine tris(2-chloroacetamidoethyl)amine, 1,2-bis-(2-(chloroacetamido) ethoxy)ethane, tris(acetamidoethyl)amine, bis-acetamidomethyl ether, bis-acetamnidoethyl ether, .alpha.,.epsilon.-bis-acetyllysine, lysine, and 1,8-bis-acetamido-3,6dioxa-octane.

8. The multimer of claim 6, wherein the radioisotope is selected from the group consisting of iodine-125, iodine-131, astatine-211, scandium-47, copper-67, gallium-72, yttrium-90, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, and bismuth-212.

9. A reagent comprising:

a) a linear peptide having a formula:

wherein

X.sup.1 is H, lower alkyl or substituted alkyl, aryl or substituted aryl, alkanoyl or substituted alkanoyl, aroyl or substituted aroyl, or a hydrophilic moiety not greater than 1500 Daltons in formula weight;

A.sup.1, A.sup.2 and C.sup.1 are each independently a lipophilic D-amino acid, a lipophilic L-amino acid, S-alkylated cysteine, penicillamine, homocysteine, or homohomocysteine;

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, or Ain;

B.sup.2 is D-Trp or L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Aec, Apc, Aes, or Aps;

B.sup.4 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, or Aib;

C.sup.2 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, Nal, or Aib;

X.sup.2 is --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear alkyl, lower cyclic alkyl, or substituted with a hydrophilic moiety; and

b) a radiolabel-binding moiety covalently linked to a residue of said peptide other than B.sup.1, B.sup.2, B.sup.3, B.sup.4 or B.sup.4.

10. The reagent of claim 9, wherein the radioisotope-binding moiety has a formula selected from the group consisting of:

a) C(pgp).sup.s -(aa)-C(pgp).sup.s wherein (pgp).sup.s is H or a thiol protecting group and (aa) is any .alpha.- or .beta.-amino acid;

b) a radiolabel-binding moiety comprising a single thiol having a formula:

wherein

A is H, HOOC, H.sub.2 NOC, (amino acid or peptide)-NHOC, (amino acid or peptide)-OOC or R"";

B is H, SH, --NHR'", --N(R'")-(amino acid or peptide), or R"";

X is H, SH, --NHR'", --N(R'")-(amino acid or peptide) or R"";

Z is H or R"";

R', R", R'" and R"" are independently H or lower straight or branched chain or cyclic alkyl;

n is 0, 1 or 2;

and where B is --NHR'" or --N(R'")-(amino acid or peptide), X is SH, and n is 1 or 2;

where X is --NHR'" or --N(R'")-(amino acid or peptide), B is SH, and n is 1 or 2;

where B is H or R"", A is HOOC, H.sub.2 NOC, (amino acid or peptide)-NHOC, (amino acid or peptide)-OOC, X is SH, and n is 0 or 1;

where A is H or R"", then where B is SH, X is --NHR'" or --N(R'")-(amino acid or peptide) and where X is SH, B is --NHR'" or --N(R'")-(amino acid or peptide);

where X is H or R"", A is HOOC, H.sub.2 NOC, (amino acid or peptide)-NHOC, (amino acid or peptide)-OOC and B is SH;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, (amino acid or peptide)-NHOC, (amino acid or peptide)-OOC, B is SH and n is 0;

c) ##STR7##

wherein

X=H or a protecting group;

(amino acid)=any amino acid;

d) ##STR8##

wherein

X=H or a protecting group;

(amino acid)=any amino acid; or

e) ##STR9##

wherein

each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear lower alkyl, cyclic lower alkyl, aryl, heterocyclyl, combination thereof, or a substituted derivative thereof; and

f) ##STR10##

wherein

each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear lower alkyl, cyclic lower alkyl, aryl, heterocyclyl, a combination thereof or a substituted derivative thereof V=H or --CO-peptide;

R'=H or peptide;

and wherein when V=H, R'=peptide and when R'=H, V=--CO-peptide.

11. The reagent of claim 10, wherein the radioisotope-binding moiety has the formula

and (pgp).sup.s has a formula

wherein R is a lower alkyl having 1 to 6 carbon atoms, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

12. The reagent of claim 10, wherein the radioisotope-binding moiety has the formula: ##STR11##

13. A radiotherapeutic multimer comprising:

a) at least two copies of a reagent comprising:

i) a linear peptide having a formula:

wherein

X.sup.1 is H, lower alkyl or substituted alkyl, aryl or substituted aryl, alkanoyl or substituted alkanoyl, aroyl or substituted aroyl, or a hydrophilic moiety not greater than 1500 Daltons in formula weight;

A.sup.1, A.sup.2 and C.sup.1 are each independently a lipophilic D-amino acid, a lipophilic L-amino acid, S-alkylated cysteine, penicillamine, homocysteine, or homohomocysteine;

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, or Ain;

B.sup.2 is D-Trp or L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Aec, Apc, Aes, or Aps;

B.sup.4 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, or Aib;

C.sup.2 is D-Thr, L-Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, Nal, or Aib;

X.sup.2 is --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear alkyl, lower cyclic alkyl, a substituted derivative thereof, or substituted with a hydrophilic moiety; and

ii) a radiolabel-binding moiety covalently linked to a residue of said peptide other than B.sup.1, B.sup.2, B.sup.3, B.sup.4 or B.sup.4 ;

b) a polyvalent linker covalently linked to each of said peptides; wherein the molecular weight of said multimer is less than about 20,000 daltons; and

c) a cytotoxic radioisotope.

14. The multimer of claim 13, wherein the linker is selected from the group consisting of bis-succinimidylmethylether, 4-(2,2-dimethylacetyl)benzoic acid, N-(2-(N',N'-bis(2-succinimidoethyl)aminoethyl))-N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, tris(succinimidylethyl)amine tris(2-chloroacetamidoethyl)amine, 1,2-bis-(2-(chloroacetamido) ethoxy)ethane, tris(acetamidoethyl)amine, bis-acetamidomethyl ether, bis-acetamidoethyl ether, .alpha.,.epsilon.-bis-acetyllysine, lysine, and 1,8-bis-acetamido-3,6dioxa-octane.

15. The multimer of claim 13, wherein the radioisotope is selected from the group consisting of iodine-125, iodine-131, astatine-211, scandium-47, copper-67, gallium-72, yttrium-90, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, and bismuth-212.

16. A reagent having a formula selected from the group consisting of:

F.sub.D FYW.sub.D KTFTGGCK.amide;

DDD.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

Ac.DDD.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

Hca.G.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

F.sub.D FYW.sub.D KTFTC.sub.Acm GC.sub.Acm.amide;

F.sub.D FYW.sub.D KTFTGGC.amide;

F.sub.D FYW.sub.D KTFT(.epsilon.-K)GC.amide;

(Trc.imide).sub.2 K.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCRR.amide;

Trc(Trc.imide)K.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCRR.amide;

(Trc.imide)Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCR.amide;

F.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCR.amide;

K.sub.D KKK.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKDKD.amide;

K.sub.D KKK.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCDD.amide;

(Trc).sub.2 K.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

Hca.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

(2-ketogulonyl)F.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

KKKK.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCDDDD.amide;

Ac.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

Ac.KKKKK.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

(2-ketogulonyl)F.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GC amide;

Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

DDDD.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKKKK.amide;

(DTPA)Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKK.amide;

(DTPA)Nal.sub.D.Cpa.YW.sub.D KTFTC.sub.Acm GC.sub.Acm.amide;

Ac.KKKKK.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GC.amide; and

KDKD.Nal.sub.D.Cpa.YW.sub.D KTFT(.epsilon.-K)GCKDKD.amide.

17. The reagent of claim 16, further comprising a cytotoxic radioisotope.

18. The reagent of claim 17, wherein the radioisotope is selected from the group consisting of scandium-47, copper-67, gallium-72, yttrium-90, iodine-125, iodine-131, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, bismuth-212 and astatine-211.

19. The reagent of claim 16, further comprising a radioisotope selected from the group consisting of gallium-68, technetium-99m, indium-111, and iodine-123.

20. A kit comprising a sealed vial containing a predetermined quantity of the reagent of claim 16 and a sufficient amount of a reducing agent to label the reagent with technetium-99m, rhenium-186, or rhenium-188.

21. The kit of claim 15, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

22. A method of labeling the reagent of claim 16 comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

23. The method of claim 22, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

24. A method of promoting regression of a somatostatin receptor-bearing tumor in a mammal comprising the step of administering an effective therapeutic amount of the agent of claim 1 to the mammal.

25. A method of promoting regression of a somatostatin receptor-bearing tumor in a mammal comprising the step of administering an effective therapeutic amount of the multimer of claim 6 to the mammal.

26. A method of promoting regression of a somatostatin receptor-bearing tumor in a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 9 to the mammal.

27. A method of promoting regression of a somatostatin receptor-bearing tumor in a mammal comprising the step of administering an effective therapeutic amount of the multimer of claim 13 to the mammal.

28. A method of promoting regression of a somatostatin receptor-bearing tumor in a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 16 to the mammal.

29. A method of promoting regression of a somatostatin receptor-bearing tumor to a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 17 to the mammal.

30. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the agent of claim 1 to the mammal.

31. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the multimer of claim 6 to the mammal.

32. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 14 to the mammal.

33. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the multimer of claim 13 to the mammal.

34. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 16 to the mammal.

35. A method of reducing hormonal hypersecretion in a mammal comprising the step of administering an effective therapeutic amount of the reagent of claim 17 to the mammal.

36. A method of imaging a somatostatin receptor-bearing site in a mammal comprising the steps of administering a diagnostically effective amount of the reagent of claim 19 the mammal and detecting radioactivity localized at the site.

37. The method of claim 36, wherein the radioisotope is technetium-99m.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc